Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. announced the US commercial launch of Relistor (methylnaltrexone bromide) Tablets, which is now available for prescribing. Relistor tablets (450 mg once daily) were approved by the US Food and Drug Administration (FDA) for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain on July 19, 2016.
"We are very pleased to launch Relistor Tablets in the US and provide an exceptional new treatment option for the millions of patients who suffer from extreme discomfort due to OIC," said Joseph C. Papa, chief executive officer of Valeant. "This new method of delivery for Relistor offers healthcare professionals a novel alternative to address the treatment of OIC – a growing need in pain management – and demonstrates Valeant's continued commitment to delivering innovative products that improve people's lives."
In addition, Relistor tablets will be highlighted during poster presentations at PAINWeek, the largest US pain conference for frontline clinicians, in Las Vegas, Nevada, from September 6-10.
The Relistor tablets data will also be presented by Steven Simon, M.D., Professor of Pathology, University of Miami Health System, during a product theatre, "Opioid-Induced Constipation When Reliable and Rapid Relief Matters," on September 9.